 Poseida announced a collaboration agreement on Aug.3 focused on allogeneic CAR-T Program in hematologic cancers with Roche, potentially worth 6 billion; 110 million upfront, 110 million in near-term milestones; other collaboration benefits. This is Poseidas second major collaboration deal following Takeda collaboration agreement focused on gene therapy products announced in October 2021. 